@icosociety.bsky.socialIt's official: GC-OS is heading to Tokyo in 2027 šÆšµ
Want to be the first to know about updates for #GCOS27? Join our mailing list š
#GCOS27 #CardioOncology #CardioOnc #Tokyo #Japan #CardioOncologyConference #HealthcareConference
@icosociety.bsky.socialAfter lunch at #GCOS26: the IC-OS Champions League Final is on! š
Who takes home the silverware and the title of cardio-oncology knowledge champs? Then we explore the cardiovascular challenges facing cancer survivors post-treatment.
@icosociety.bsky.socialUp Next at #GCOS26 š
Our second amyloidosis session on the latest treatments, then a conversation on cardiotoxicity from new-generation cancer therapies. Lunch follows, with the product theatre sponsored by @Alnylam š½ļø
@icosociety.bsky.social#GCOS26 Day 2 starts now! š«
Today: exercise and cardio-oncology, amyloidosis, and limiting cardiotoxicity. See you in the Virginia Room at 8:00 AM.
@icosociety.bsky.socialWelcome back from lunch! š
Afternoon at #GCOS26 starts with our first Amyloidosis session on diagnosis and clinical case studies.
Then, 2026 #ThomasForceAward winner Dr. Alex Lyon š¬š§ presents "Ten Laws of Cardio-Oncology."
@icosociety.bsky.socialThat's a wrap on the meeting portion of Day 1 at #GCOS26! š
But we're not through yet ā join us for our poster session, followed by dinner in the Colony Room (tickets required). š½ļø
#GCOS26 #CardioOncology #CardioOnc #CardioOncologyConference #WilliamsburgVA
@icosociety.bsky.socialEric Harrison, MD: IC-OS Board Member, cardiac imaging pioneer, and founder of Cardio-Orthopaedics.
Today at #GCOS26, we honor his legacy by inducting him into the IC-OS Hall of Fame. š
Learn more: ic-os.org/HOF2026
@icosociety.bsky.socialCongrats again to Dr Alexander Lyon, your 2026 Thomas Force Award Winner!
#GCOS26 #GCOS2026 #GCOS #ThomasForce #ThomasForceAward #CardioOncology #CardioOnc #CancerCare #CancerTreatment
@icosociety.bsky.socialAfter the break at #GCOS26 āļø
š IC-OS leaders on the year's progress
š
Our newest IC-OS Hall of Fame inductee
š The Young Investigator Awards
@icosociety.bsky.social
@icosociety.bsky.socialUp Next at #GCOS26 š
Late morning kicks off with a discussion on how AI is changing cardio-oncology ā followed by the year's best research. Then it's lunch and a tour of the product theatre with sponsor @AstraZeneca.
@icosociety.bsky.socialPatients are the reason we are all here for #GCOS26 ā¤ļø
Cardio-oncology patient Tara Daudani is here with us today to share her perspective on how cardio-oncology has impacted her life.
Thank you Tara for sharing your story!
@icosociety.bsky.social@icosociety.bsky.social#GCOS26 is officially here! š¤©
A full day of global insights and networking starts at 8am sharp. Grab a coffee and get acquainted with the schedule š
@icosociety.bsky.social
@medliveofficial.bsky.socialHow can ADT strategies impact CV outcomes in prostate cancer? Explore case-based guidance on CV risk assessment, treatment selection, monitoring, and multidisciplinary care.
ā¶ļø Access on-demand: vist.ly/5hr45
@aspcardio.bsky.socialLearn how ADT strategies impact cardiovascular outcomes in prostate cancer patients through expert case discussions. ā¶ļø Watch: https://bit.ly/4cwo6xg #ProstateCancer #CardiovascularHealth #CardioOncology #MedicalEducation
@icosociety.bsky.socialDuring #cancer treatment, Jackie Ellis appeared to develop ICI myocarditis.
This week on #HeartToHeart, she & cardio-oncologist Josh Mitchell, MD share how #oncology-#cardiology teamwork kept her care on track.
š§ tinyurl.com/mu93mbfp
@j-cardio-oncol.bsky.socialNew systematic review & meta-analysis: PD-1/PD-L1 inhibitor combos vs controls raise CV adverse event risk, highest in targeted combos, with elevated risk in lung, multiple myeloma, urothelial and head/neck cancer patients. #CardioOncology #ImmunoOncology https://doi.org/10.1097/co9.0000000000000021